Skip to main content

Table 4 Best Objective Response by irRC and RECIST v1.1

From: Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

n (%)

irRC

RECIST

Immunotherapy-Naive (n = 39)

Prior Immunotherapy (n = 11)

Immunotherapy-Naive (n = 39)

Prior Immunotherapy (n = 11)

Objective response rate

10 (25.6)

0

9 (23.1)

0

 Complete response

3 (7.7)

0

3 (7.7)

0

 Partial response

7 (17.9)

0

6 (15.4)

0

Stable disease

15 (38.5)

4 (36.4)

10 (25.6)

3 (27.3)

Disease control rate

25 (64.1)

4 (36.4)

19 (48.7)

3 (27.3)

Progressive disease

7 (17.9)

5 (45.5)

15 (38.5)

6 (54.5)

Missing

7 (17.9)

2 (18.2)

5 (12.8)

2 (18.2)

  1. irRC immune-related response criteria, RECIST Response Evaluation Criteria in Solid Tumors